Introduction: Graves’ disease associated with comorbidities can increase morbidity and mortality. Our objective was to describe the epidemiological, clinical, therapeutic and evolutionary aspects of comorbidities associated with Graves’ disease at the Abass hospital center, Ndao. Methods: This was a cross-sectional and descriptive study conducted from January 2020 to December 2020. It focused on patients followed for Graves’ disease at Abass hospital, Ndao de Dakar. Epidemiological, clinical, therapeutic and evolutionary data were evaluated. Results: Three hundred and three eighteen (318) cases were collected, 70 of which had comorbidities (51.15%). The average age was 38.45 years with extremes ranging from 15 to 71 years. Women represented 91.42% of patients. A consultation delay of more than one year was noted in 24.29%. Cardiovascular comorbidities were dominated by hypertension with 30%. Graves’ disease was associated with an evolving pregnancy in 10 women. Endocrine comorbidities were dominated by type 1 diabetes noted in 8.57% each. Biermer’s disease was noted in 2 patients. Female gender was the most common etiological factor of Graves’ disease noted in 64 patients (91.42%). A hereditary predisposition existed in 4 patients (5.71%), stress was noted in 7 patients (10%). 43 patients were under thyrozol (61.42%), 41 patients were on propranolol (58.57%), 14 patients were on carbimazole (20%). A good balance was noted in 44 cases (68.75%) after 9 months of treatment. Conclusion: Graves’ disease is a public health problem with nonspecific signs. It requires screening and treating comorbidities to reduce morbidity and mortality.
References
[1]
Wémeau, J.L., Carnaille, B. and Marchandise, X. (2007) Treatments for Hyperthyroidism. Elsevier.
[2]
Jerome, M. (2020) Hershman, Hyperthyroidism (Thyrotoxicosis), MD, MS, David Geffen School of Medicine at UCLA Latest Revision Total Sept.
[3]
Thirion, M., Percheron, S. and Mira, J. (2006) Thyrotoxicose. Réanimation, 15, 497-505. https://doi.org/10.1016/j.reaurg.2006.10.002
[4]
Pearce, E.N. (2006) Diagnosis and Management of Thyrotoxicosis. British Medical Journal, 332, 1369-1373. https://doi.org/10.1136/bmj.332.7554.1369
[5]
Goichot, B., Caron, P., Landron, F. and Bouée, S. (2015) Clinical Presentation of Hyperthyroidism in a Large Representative Sample of Outpatients in France: Relationships with Age, Aetiology and Hormonal Parameters. Clinical Endocrinology, 84, 445-451. https://doi.org/10.1111/cen.12816
[6]
Nouedoui, C., Moukouri, E. and Juimo, A.G. (1999) Hyperthyroidism in Yaoundé, Cameroon: Some Epidemiological, Etiological and Therapeutic Aspects: Review of Our Experience. Black African Medicine, 46, 192-198.
[7]
Djelo Diallo, B., Diallo, A., Mady Camara, L., Diallo, M., Camara, S., Bah, B., et al. (2020) Development of a Prognosis Nomogram of Treatment Outcomes for MDR-Tuberculosis in Guinea (Conakry): A Retrospective Cohort Analysis. Central African Journal of Public Health, 6, 33-41. https://doi.org/10.11648/j.cajph.20200601.16
[8]
Dago, K., Lokrou, F., Abodo, D., Yao, H. and Kouamé, K. (2019) Hyperthyroidism in Abidjan: Clinical, Biological, Therapeutic and Evolutionary Aspects of 399 Cases. Health Sciences and Diseases, 20, 23-26.
[9]
Diagne, N., Faye, A., Ndao, A.C., Djiba, B., Kane, B.S., Ndongo, S., et al. (2016) Aspects épidémiologique, clinique, thérapeutique et évolutif de la maladie de Basedow en Médecine Interne au CHU Ledantec Dakar (Sénégal). Pan African Medical Journal, 25, Article 6. https://doi.org/10.11604/pamj.2016.25.6.7868
[10]
Hadj Ali, I., Khiari, K., Chérif, L., Abdallah, N.B., Maïz, H.B., Hajri, H., et al. (2004) Traitement de la maladie de Basedow: 300 cas. La Presse Médicale, 33, 17-21. https://doi.org/10.1016/s0755-4982(04)98466-7
[11]
Toft, A.D., Hunter, W.M., Barnes, E.W., Seth, J. and Irvine, W.J. (1973) Raised Plasma-Thyroid-Stimulating-Hormone Levels in Thyrotoxic Patients Treated with Iodine-131. The Lancet, 302, 644-645. https://doi.org/10.1016/s0140-6736(73)92481-1
[12]
Mbodj, M., Guerrouj, H., Amjad, I. and Ben Raïs, N.A. (2009) Apport de l’iode 131 dans le traitement de la maladie de Basedow dans le service de médecine nucléaire de l’hôpital Ibn Sina de Rabat. MédecineNucléaire, 33, 592-598. https://doi.org/10.1016/j.mednuc.2009.07.019
[13]
Oumar, N. (2004) Surgical Treatment of Graves’ Disease State. University of Dakar.
[14]
Marhari, H., El Khadir, S., Salhi, H. and El Ouahabi, H. (2018) L’impact de la maladie de Basedow sur l’évolutivité de la grossesse: À propos de 12 cas. Annales d’Endocrinologie, 79, 375. https://doi.org/10.1016/j.ando.2018.06.568
[15]
Khatraty, S. and Saad, Booh. (2001) Surgical Treatment of Basedow’s Disease. University of Dakar.
[16]
Anaddam, S., Barakate, K. and Ouleghzal, H. (2011) Graves’ Disease, about 40 Cases. Annals of Endocrinology, 2, 375-401.
[17]
Alla, A., Karrou, M., Aynaou, H. and Latrech, H. (2018) Maladie de Basedow: Profil épidémiologique, clinique, thérapeutique et évolutif—À propos de 35 cas. Annales d’Endocrinologie, 79, 355-356. https://doi.org/10.1016/j.ando.2018.06.499
[18]
Perrine, A.L., Lecoffre, C., Blacher, J. and Olié, V. (2019) High Blood Pressure in France: Prevalence, Treatment and Control in 2015 and Developments since 2006.
[19]
Rekik, N., Mnif, F., Ben Salah, S., Mnif Feki, M., Charfi, N., Masmoudi, H., et al. (2009) P254 Diabète de type 1 et maladies thyroïdiennes auto-immunes au cours des polyendocrinopathies auto-immunes: À propos de 60 cas. Diabetes & Metabolism, 35, A87. https://doi.org/10.1016/s1262-3636(09)72052-x
[20]
Bennour, M., Rojbi, I., Rezgani, I., Ben Nacef, I., Mchirgui, N., Khiari, K., et al. (2017) Fréquence des pathologies auto-immunes au cours du diabète type 1. Annales d’Endocrinologie, 78, 426. https://doi.org/10.1016/j.ando.2017.07.684
[21]
Ach, M.T., Akkari, I., Maaroufi, A., Kacem, M., Chaieb, M. and Ach, K. (2016) Anémie de Biermer et maladies auto-immunes: À propos de 28 cas. Annales d’Endocrinologie, 77, 375. https://doi.org/10.1016/j.ando.2016.07.402
[22]
Mtir, M., Ayari, M., Bourguiba, R., Chehaider, A., Boudokhane, M., Abdelaali, I., et al. (2023) La maladie de Biermer et les maladies auto-immunes: Prévalence et aspects cliniques. La Revue de Médecine Interne, 44, A248-A249. https://doi.org/10.1016/j.revmed.2023.04.232
Delévaux, I., Chamoux, A. and Aumaître, O. (2013) Stress et auto-immunité. La Revue de Médecine Interne, 34, 487-492. https://doi.org/10.1016/j.revmed.2012.10.3662
Allannic, H., Fauchet, R., Orgiazzi, J., Orgiazzi, A.M., Genetet, B., Lorcy, Y., et al. (1990) Antithyroid Drugs and Graves’ Disease: A Prospective Randomized Evaluation of the Efficacy of Treatment Duration. The Journal of Clinical Endocrinology & Metabolism, 70, 675-679. https://doi.org/10.1210/jcem-70-3-675
